Currently, there is no known clinical evidence that rituximab increases the rate of subsequent primary malignancies; however, some studies have raised the question of increased melanoma risk following rituximab treatment for non-Hodgkin lymphoma. We report three interesting cases of suspected rituximab-induced melanoma. We hypo thesize that this association is secondary to rituximab-driven shifts in the immunologic balance. Based on these cases, it is possible that the number of post-rituximab melanoma cases is underreported. Further mechanistic research into individual cases and population-level studies are required to better define association and risk; however, given the increasing prevalence of oncologic and nononcologic rituximab use, awareness across all fields is essential. Received 27 September 2021 Accepted 28 October 2021 Correspondence to Anastasios Dimou, MD, Division of Medical Oncology, Mayo Clinic, 200 1st St NW, Rochester, MN 55902, USA, Tel: 507 773 0569; e-mail: dimou.anastasios@mayo.edu Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
No comments:
Post a Comment